SCHEMBL30795263

SCHEMBL30795263

Cc1cc(N2CCOCC2)cc(C(F)(F)F)c1NC(=O)Cc1ccc(F)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 1/20 0.50
PPARG P37231 1/20 0.46
MAPT P10636 2/20 0.46
P2RX7 Q99572 4/20 0.45
EPHX2 P34913 2/20 0.44
KCNQ2 O43526 2/20 0.43
AKT1 P31749 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
PIK3CD O00329 3/20 0.41
PIK3CA P42336 3/20 0.41
PIK3CB P42338 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP3A4 P08684 1/20 0.40
PIK3CG P48736 1/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432710 1.00 GPR183 (0.50) GPR183PPARGMAPTP2RX7EPHX2
SCHEMBL2435553 0.91 GPR183 (0.56) GPR183PPARGMAPTP2RX7EPHX2
SCHEMBL30795653 0.85 MAPT (0.57) GPR183PPARGMAPTP2RX7EPHX2
SCHEMBL2435168 0.85 MAPT (0.57) GPR183PPARGMAPTP2RX7EPHX2
SCHEMBL2434583 0.81 GPR183 (0.71) GPR183PPARGMAPTP2RX7KCNQ2
SCHEMBL2435159 0.81 KCNQ2 (0.60) KCNQ2
SCHEMBL30795268 0.81 KCNQ2 (0.60) KCNQ2
SCHEMBL2439725 0.80 SMN1; SMN2 (0.52) GPR183MAPTEPHX2KCNQ2AKT1
SCHEMBL30814215 0.80 MAPT (0.55) MAPTKCNQ2SMN1; SMN2MEN1KMT2A
SCHEMBL2437088 0.80 MAPT (0.55) MAPTKCNQ2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed